Theriva Biologics (TOVX) Intangibles (2022 - 2026)
Theriva Biologics (TOVX) posted quarterly Intangibles of $19.2 million for Q1 2026, up 6.31% year-over-year from $18.1 million in Q1 2025, and down 2.01% quarter-over-quarter from $19.6 million in Q4 2025.
Theriva Biologics (TOVX) Intangibles (2022 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Intangibles for 5 consecutive years, with $19.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Intangibles rose 6.31% year-over-year to $19.2 million; the TTM figure through Mar 2026 stood at $19.2 million (up 6.31% YoY), while the FY2025 annual figure was $19.6 million, up 13.03% from the prior year.
- Intangibles slipped to $19.2 million in Q1 2026 per TOVX's latest filing, from $19.6 million in the prior quarter.
- Across five years, Intangibles topped out at $21.9 million in Q1 2022 and bottomed at $17.4 million in Q4 2024.
- Historically, Intangibles has averaged $19.2 million across 5 years, with a median of $19.3 million in 2024.
- Annual changes were most pronounced in 2024 — Intangibles decreased 12.13% — and 2025, when it rose 13.03%.
- Theriva Biologics' Intangibles stood at $19.2 million in 2022, then grew by 3.16% to $19.8 million in 2023, then decreased by 12.13% to $17.4 million in 2024, then grew by 13.03% to $19.6 million in 2025, then decreased by 2.01% to $19.2 million in 2026.
- Business Quant data shows TOVX's Intangibles at $19.2 million in Q1 2026, $19.6 million in Q4 2025, and $19.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 60.96 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 93.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Theriva Biologics | 10.64 Mn | 10.64 Mn | - | 19.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.06 Mn |
| Mar 31, 2026 | 19.23 Mn |
| Dec 31, 2025 | 19.62 Mn |
| Sep 30, 2025 | 19.61 Mn |
| Jun 30, 2025 | 19.62 Mn |
| Mar 31, 2025 | 18.08 Mn |
| Dec 31, 2024 | 17.36 Mn |
| Sep 30, 2024 | 19.80 Mn |
| Jun 30, 2024 | 19.18 Mn |
| Mar 31, 2024 | 19.32 Mn |
| Dec 31, 2023 | 19.76 Mn |
| Sep 30, 2023 | 18.93 Mn |
| Jun 30, 2023 | 19.48 Mn |
| Mar 31, 2023 | 19.47 Mn |
| Dec 31, 2022 | 19.15 Mn |
| Sep 30, 2022 | 17.54 Mn |
| Jun 30, 2022 | 17.84 Mn |
| Mar 31, 2022 | 21.87 Mn |